The comparison of IL-17 levels in patients with unstable angina before and after medical treatment.

Q3 Medicine

Human Antibodies Pub Date : 2022-01-01 DOI:10.3233/HAB-210446

Ahmad Boluri, Hosseinali Khazaei, Narjes Sargolzaei, Hanie Olfat Miri, Bahman Khazaei

{"title":"The comparison of IL-17 levels in patients with unstable angina before and after medical treatment.","authors":"Ahmad Boluri, Hosseinali Khazaei, Narjes Sargolzaei, Hanie Olfat Miri, Bahman Khazaei","doi":"10.3233/HAB-210446","DOIUrl":null,"url":null,"abstract":"Background: Interleukin (IL)-17 plays a central role in orchestrating the cytokine cascade and accelerates atherosclerosis and plaque vulnerability in animal models. However, epidemiological data evaluating the role of IL-17 levels in unstable angina are lacking. The aim of our study is to evaluate and compare the IL-17 levels in unstable angina (UA) cases before and after treatment.Methods: This cross-sectional study was performed from July to October 2018 in Ali Iben-abitaleb heart center, Zahedan, Iran. 48 patients with UA in the age range of below 50 years entered the study. All demographic, past medical history, physical examination, electrocardiogram (EKG or ECG), and transthoracic echocardiogram (TTE) data were collected. Serum level of IL-17 was measured using enzyme-linked immunosorbent assay (ELISA) method. In all the tests, P< 0.05 was considered as statistically significant. All data analyses were performed using the SPSS 13.0 software (SPSS Inc., Chicago, Illinois, USA).Results: In this study, 48 UA patients, including 34 women and 16 men with a mean age of 56.60 years were included in the study. The mean serum level of interleukin 17 after treatment (65.13 ± 53.29 pg/dl) was significantly lower than Its level before treatment (94.89 ± 51.25 pg/dL) (P< 0/05).Conclusion: Our findings point towards a role of inflammation in the form of increased activity of IL-17 in UA patients and thus suggest that IL-17-driven inflammation may play a role in the promotion of clinical instability in patients with coronary artery disease.","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"30 1","pages":"25-29"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-210446","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Antibodies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/HAB-210446","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Interleukin (IL)-17 plays a central role in orchestrating the cytokine cascade and accelerates atherosclerosis and plaque vulnerability in animal models. However, epidemiological data evaluating the role of IL-17 levels in unstable angina are lacking. The aim of our study is to evaluate and compare the IL-17 levels in unstable angina (UA) cases before and after treatment.

Methods: This cross-sectional study was performed from July to October 2018 in Ali Iben-abitaleb heart center, Zahedan, Iran. 48 patients with UA in the age range of below 50 years entered the study. All demographic, past medical history, physical examination, electrocardiogram (EKG or ECG), and transthoracic echocardiogram (TTE) data were collected. Serum level of IL-17 was measured using enzyme-linked immunosorbent assay (ELISA) method. In all the tests, P< 0.05 was considered as statistically significant. All data analyses were performed using the SPSS 13.0 software (SPSS Inc., Chicago, Illinois, USA).

Results: In this study, 48 UA patients, including 34 women and 16 men with a mean age of 56.60 years were included in the study. The mean serum level of interleukin 17 after treatment (65.13 ± 53.29 pg/dl) was significantly lower than Its level before treatment (94.89 ± 51.25 pg/dL) (P< 0/05).

Conclusion: Our findings point towards a role of inflammation in the form of increased activity of IL-17 in UA patients and thus suggest that IL-17-driven inflammation may play a role in the promotion of clinical instability in patients with coronary artery disease.

查看原文本刊更多论文

不稳定型心绞痛患者用药前后IL-17水平的比较

背景:在动物模型中，白细胞介素(IL)-17在协调细胞因子级联和加速动脉粥样硬化和斑块易损性中起核心作用。然而，评估IL-17水平在不稳定型心绞痛中的作用的流行病学数据缺乏。本研究的目的是评估和比较不稳定型心绞痛(UA)患者治疗前后的IL-17水平。方法:本横断面研究于2018年7月至10月在伊朗扎黑丹Ali Iben-abitaleb心脏中心进行，纳入48例年龄在50岁以下的UA患者。收集所有人口统计、既往病史、体格检查、心电图(EKG或ECG)和经胸超声心动图(TTE)数据。采用酶联免疫吸附法(ELISA)检测血清IL-17水平。所有检验均以P< 0.05为差异有统计学意义。所有数据分析使用SPSS 13.0软件(SPSS Inc.， Chicago, Illinois, USA)进行。结果:本研究纳入48例UA患者，其中女性34例，男性16例，平均年龄56.60岁。治疗后血清白细胞介素17的平均水平(65.13±53.29 pg/dl)显著低于治疗前(94.89±51.25 pg/dl) (P< 0/05)。结论:我们的研究结果指出炎症在UA患者中以IL-17活性增加的形式发挥作用，因此表明IL-17驱动的炎症可能在冠状动脉疾病患者的临床不稳定中起促进作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Antibodies Medicine-Immunology and Allergy

CiteScore

3.50

自引率

0.00%

发文量

期刊介绍： Human Antibodies is an international journal designed to bring together all aspects of human hybridomas and antibody technology under a single, cohesive theme. This includes fundamental research, applied science and clinical applications. Emphasis in the published articles is on antisera, monoclonal antibodies, fusion partners, EBV transformation, transfections, in vitro immunization, defined antigens, tissue reactivity, scale-up production, chimeric antibodies, autoimmunity, natural antibodies/immune response, anti-idiotypes, and hybridomas secreting interesting growth factors. Immunoregulatory molecules, including T cell hybridomas, will also be featured.